7-р сарын 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
ACT Therapeutics болон GenScript ProBio нар ACT Therapeutics-ийн Advanced CAR-T платформын (ACT платформ) эхний дамжуулах хоолойн плазмид ба вирусын векторуудыг боловсруулах, үйлдвэрлэх гэрээнд гарын үсэг зурах шатандаа явж байна. ACT Therapeutics-ийн дараагийн дамжуулах хоолойн хувьд. Гэрээ нь ACT Therapeutics-ийн дэвшилтэт CAR-T платформын эхний дамжуулах хоолойд плазмид ба вирусын вектор үйлдвэрлэх ажлыг хамарна.
Энэхүү гэрээний үр дүнд GenScript ProBio нь ACT эмчилгээний ACT платформыг дэмжих чадвартай дэлхийн түншийн статустай болсон.
ACT платформ нь хорт хавдрын эсрэгтөрөгчийг дархлааны эсүүдэд оруулах замаар хорт хавдрын эсрэгтөрөгчийг онилох шинэ үеийн эс ба генийн эмчилгээний технологи юм. Эдгээр генүүд нь вирусын векторуудыг ашиглан дархлааны эсүүдэд дамждаг. GenScript ProBio нь өндөр чанартай вирусын вектор процессыг хөгжүүлж, GMP үйлдвэрлэх нэг цэгийн үйлчилгээний платформыг эзэмшдэг бөгөөд эдгээр нь хоёулаа эсийн болон генийн эмчилгээг хөгжүүлэхэд шаардлагатай байдаг.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing цусны хавдар. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, CEO of GenScript ProBio, said, “We are very happy to cooperate with ACT therapeutics in strategic partnership, and we are looking forward to support ACT Therapeutics’ ACT platform as a global partner through our accumulated technology.”
ACT Therapeutics-ийн гүйцэтгэх захирал Seogkyoung-Kong хэлэхдээ, "Бид GenScript ProBio-той стратегийн түншлэлээр дамжуулан ACT платформыг дэлхий даяар бий болгох бэлтгэл ажлыг дуусгасан. Бид галд тэсвэртэй, эмчлэх боломжгүй хатуу хорт хавдрыг эмчлэх эмчилгээний хөгжлийг хурдасгах болно."
GenScript ProBio-ийн тухай
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
GenScript ProBio нь "Хамтран ажиллах замаар инноваци" гэсэн эрхэм зорилгынхоо дагуу биологийн эмийг илрүүлэхээс эхлээд худалдаанд гаргах хүртэлх хугацааг богиносгож, судалгаа шинжилгээний зардлыг эрс бууруулж, эрүүл ирээдүйг бий болгоход үйлчлүүлэгчдэд туслах зорилготой.
